Skip to main
DCTH

Delcath Systems (DCTH) Stock Forecast & Price Target

Delcath Systems (DCTH) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Delcath Systems Inc has demonstrated significant growth potential, with Hepzato procedure volume increasing by 140% in 2025, underscoring heightened physician utilization and commercial adoption of its Melphalan Hydrochloride for Injection and Delcath Hepatic Delivery System. The company's liquidity position is strong, with a year-end cash balance of $91.0 million, reflecting improved operational efficiency and the financial flexibility to support its expansion initiatives. Expectations for continued salesforce growth and favorable clinical data, particularly from the CHOPIN trial, suggest a positive trajectory for referrals and treatment adoption, positioning Delcath favorably for sustained market presence and revenue growth in 2026 and beyond.

Bears say

Delcath Systems Inc. has revised its full-year revenue expectations downward to $83M-$85M, reflecting a significant decrease from prior projections of $93M-$96M, primarily due to a slowdown in new site activations and a dramatic drop in new patient starts attributed to summer seasonality and competitive clinical trials. Additionally, the company is facing challenges such as a decline in average revenue per kit related to Medicaid National Drug Rebate Agreement discounts, which have resulted in expected discounts of approximately 23% for about half of its patients. Furthermore, Delcath's ongoing cash flow negativity raises concerns regarding its ability to achieve projected revenues, contributing to a fundamentally negative outlook for its stock.

Delcath Systems (DCTH) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Delcath Systems (DCTH) Forecast

Analysts have given Delcath Systems (DCTH) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Delcath Systems (DCTH) has a Strong Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Delcath Systems (DCTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.